A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Multi-center, single stage, phase II study to evaluate the efficacy and safety of Flumatinib
in accelerated or blastic Phase chronic myelogenous leukemia patients.